Evidence Hub

Metformin-associated lactic acidosis: an insufficiently recognised problem

Manders M, van Luin M, Kramers C, Bosch FH

Nederlands tijdschrift voor geneeskunde, 2017

Abstract

Metformin-associated lactic acidosis (MALA) is a rare but potentially fatal condition that can easily be avoided. As metformin is known to facilitate the production of lactate, predisposing factors can accelerate this process. In situations of infection or dehydration, metformin can accumulate due to kidney failure, hereby increasing the risk of MALA. Despite controversy in the literature about the presence of a relationship between metformin and lactic acidosis, the severity of the condition is cause for concern and allows for preventive measurements. Awareness of this condition among patients and clinicians is insufficient, resulting in many patients continuing metformin in situations where there is an increased risk of developing MALA. Metformin can easily be discontinued temporarily without causing any harm. We emphasize the importance of temporarily discontinuing metformin in situations where the risk of lactic acidosis is increased, such as severe infection, dehydration and acute kidney insufficiency. This requires increased awareness and adequate counselling by clinicians as well as pharmacists.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free